12V Stock Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Veracyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.50 |
| 52 Week High | US$26.60 |
| 52 Week Low | US$17.50 |
| Beta | 1.64 |
| 1 Month Change | -11.17% |
| 3 Month Change | -24.57% |
| 1 Year Change | -16.67% |
| 3 Year Change | -57.32% |
| 5 Year Change | -15.97% |
| Change since IPO | 110.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 12V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.4% | -4.9% | -1.5% |
| 1Y | -16.7% | -19.9% | 0.9% |
Return vs Industry: 12V exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 12V underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 12V volatility | |
|---|---|
| 12V Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 12V's share price has been volatile over the past 3 months.
Volatility Over Time: 12V's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 815 | Marc Stapley | www.veracyte.com |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
Veracyte, Inc. Fundamentals Summary
| 12V fundamental statistics | |
|---|---|
| Market cap | €1.33b |
| Earnings (TTM) | -€69.90m |
| Revenue (TTM) | €339.21m |
3.9x
P/S Ratio-19.0x
P/E RatioIs 12V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 12V income statement (TTM) | |
|---|---|
| Revenue | US$361.05m |
| Cost of Revenue | US$112.90m |
| Gross Profit | US$248.15m |
| Other Expenses | US$322.55m |
| Earnings | -US$74.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 68.73% |
| Net Profit Margin | -20.61% |
| Debt/Equity Ratio | 0% |
How did 12V perform over the long term?
See historical performance and comparison